IV Iron Replacement for Iron Deficiency in Idiopathic Pulmonary Arterial Hypertension (IPAH) Patients

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2015 by Imperial College London
Fu Wai Hospital, Beijing, China
Information provided by (Responsible Party):
Imperial College London
ClinicalTrials.gov Identifier:
First received: October 4, 2011
Last updated: October 27, 2015
Last verified: August 2015

This study will establish whether intravenous iron replacement has clinical benefit in idiopathic pulmonary arterial hypertension.

A 24-week double-blind, randomised, placebo-controlled, crossover study will investigate whether a single dose of 1g of Ferinject® or CosmoFer improves cardiopulmonary haemodynamics, exercise capacity and quality of life and is well-tolerated.

Condition Intervention Phase
Pulmonary Arterial Hypertension
Iron Deficiency
Drug: Saline
Drug: Ferinject or CosmoFer
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: What is the Effect of Intravenous Iron Supplementation on Cardiopulmonary Haemodynamics, Exercise Capacity and Quality of Life in Patients With IPAH and Iron Deficiency?

Resource links provided by NLM:

Further study details as provided by Imperial College London:

Primary Outcome Measures:
  • Change in resting pulmonary vascular resistance (PVR) [ Time Frame: 12 weeks from baseline ] [ Designated as safety issue: No ]
    To be measured by cardiac catheterisation in wood units.

  • Change in Exercise Capacity [ Time Frame: 12 Weeks post study treatment ] [ Designated as safety issue: No ]
    Cardiac Pulmonary exercise testing at baseline and at 12 weeks interval - peak VOR2R (ml/min/kg)

Secondary Outcome Measures:
  • Difference in gas exchange at 3 minutes [ Time Frame: 12 weeks post study treatment ] [ Designated as safety issue: No ]
    Gas exchange at 3 minutes from an endurance exercise test at 80% peak work rate determined from the incremental exercise test

  • Iron indices [ Time Frame: 12 weeks post study treatment ] [ Designated as safety issue: No ]
    Iron indices - serum iron, transferrin saturations, ferritin, soluble transferrin receptor, RDW, EPO, and UIBC

  • 6 minute walk distance and Borg dyspnoea scale [ Time Frame: 12 weeks post study treatment ] [ Designated as safety issue: No ]
    6 minute walk distance (meters) and Borg dyspnoea scale (from 1-10)

  • WHO functional class [ Time Frame: 12 weeks post study treatment ] [ Designated as safety issue: No ]
    WHO Functional Class (I-IV)

  • NT-proBNP [ Time Frame: 12 weeks post study treatment ] [ Designated as safety issue: No ]
    Change in NT-proBNP (fmol/ml)

  • Quality of life [ Time Frame: 12 weeks post study treatment ] [ Designated as safety issue: No ]
    Quality of life (CAMPHOR questionnaire) and the self-reported Patient Global Assessment

  • Safety - In terms of reported adverse events [ Time Frame: 12 weeks post study treatment ] [ Designated as safety issue: No ]
    Safety - the number, occurrence and frequency of adverse events

  • Cardiac MRI [ Time Frame: 12 weeks post study treatment ] [ Designated as safety issue: No ]
    Cardiac MRI - right ventricular volumes, mass, ejection fraction, stroke volume and diastolic function (reported in mL)

Estimated Enrollment: 60
Study Start Date: October 2011
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Ferinject or CosmoFer

IV iron formulation used in Europe - Ferinject - given over 15 minutes

IV iron formulation used in China - CosmoFer - over a period of 4 to 6 hours

Drug: Ferinject or CosmoFer
Intravenous, 1000 mg iron
Placebo Comparator: Saline Drug: Saline
intravenous, no active drug

Detailed Description:
IV iron formulation used in Europe - Ferinject IV iron formulation used in China - CosmoFer

Ages Eligible for Study:   16 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Males or females aged between 18-75 years old
  2. PAH which is idiopathic, heritable or associated with anorexigens.
  3. Iron deficiency as defined by any 3 of the following criteria:

    ferritin < 100 ug/l; transferrin saturations < 22.1%; EPO > 30.5 mIU/ml or iron < 10.3 umol/l.

  4. Documented diagnosis of PAH by right heart catheterisation performed at any time prior to Screening showing: resting mean pulmonary artery pressure >25mmHg, pulmonary capillary wedge pressure =/< 15 mm Hg and normal or reduced cardiac output;
  5. 6 minute walking distance greater than 50m at entry;
  6. Stable on an unchanged PAH therapeutic regime (any combination of endothelin receptor antagonist, phosphodiesterase inhibitor or prostacyclin analogue) for at least 1 month.
  7. Able to provide written informed consent prior to any study- mandated procedures
  8. Female subjects of child-bearing potential are eligible to participate if they agree to use one of the following contraception methods:

    • Abstinence
    • Contraceptive methods with a failure rate of < 1%:
    • Oral contraceptive, either combined or progestogen alone;
    • Injectable progestogen;
    • Implants of levonorgestrel;
    • Estrogenic vaginal ring;
    • Percutaneous contraceptive patches;
    • Intrauterine device (IUD) or intrauterine system (IUS) that meets the <1% failure rate as stated in the product label;
    • Male partner(s) sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study;
    • Double barrier method: condom and occlusive cap (diaphragm or cervical/vault caps) plus vaginal spermicidal agent (foam/gel/film/cream/suppository).

Exclusion Criteria:

  1. Unable to provide informed consent.
  2. Clinically-significant renal disease (Creatinine clearance < 30 ml/min per 1.73 m2 calculated from CKD-Epi http://www.qxmed.com/renal/Calculate-CKD-EPI-GFR.php) or liver disease (including serum transaminases > 3 times upper limit of normal).
  3. Haemoglobin concentration <10 g/dl.
  4. Patients with moderate to severe hypophosphatemia as defined as <0.65mmol/L
  5. Known to have haemoglobinopathy e.g. sickle cell disease, thalassaemia.
  6. Admission to hospital related to PAH or change in PAH therapy within 1 month prior to Screening.
  7. Evidence of left ventricular disease or significant lung disease on high-resolution CT scanning or lung function as judged by the investigator
  8. Acute or chronic infection or inflammation.
  9. Significant uncontrolled asthma as judged by the investigator, eczema or atopic allergies.
  10. Females who are lactating or pregnant.
  11. Individuals known to have HIV, Hepatitis B or C or Creutzfeld-Jakob disease.
  12. Known hypersensitivity to Ferinject® or any of its excipients.
  13. Evidence of disturbances in utilisation of iron.
  14. Significant blood loss (e.g. GI bleed) within the last 3 months or history of menorrhagia.
  15. Unable to perform a Cardiopulmonary Exercise Test i.e. due to syncope or musculoskeletal factors.
  16. Patients who have received an investigational medicinal product within 30 days of entering the baseline visit
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01447628

Contact: Luke Howard, DPhil, FRCP 020 8383 3171 l.howard@imperial.ac.uk
Contact: Vijay Zala, M.Pharm, MBA 020 8383 6103 V.Zala@imperial.ac.uk

Fuwai Hospital Recruiting
Beijing, China
Contact: Vijay Zala       v.zala@imperial.ac.uk   
United Kingdom
Papworth Hospital NHS Foundation Trust Recruiting
Cambridge, United Kingdom
Principal Investigator: Karen Sheares, PhD, FRCP         
Hammersmith Hospital, Imperial College NHS Trust Recruiting
London, United Kingdom
Principal Investigator: Luke Howard, DPhil, FRCP         
Royal Hallamshire Hospital Recruiting
Sheffield, United Kingdom
Principal Investigator: David Kiely, PhD, FRCP         
Sponsors and Collaborators
Imperial College London
Fu Wai Hospital, Beijing, China
Principal Investigator: Luke Howard, DPhil, FRCP Imperial College London
  More Information

Responsible Party: Imperial College London
ClinicalTrials.gov Identifier: NCT01447628     History of Changes
Other Study ID Numbers: CRO1811 
Study First Received: October 4, 2011
Last Updated: October 27, 2015
Health Authority: United Kingdom: Research Ethics Committee
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Imperial College London:
Idiopathic pulmonary arterial hypertension (IPAH)
Iron deficiency

Additional relevant MeSH terms:
Anemia, Iron-Deficiency
Familial Primary Pulmonary Hypertension
Anemia, Hypochromic
Cardiovascular Diseases
Hematologic Diseases
Hypertension, Pulmonary
Iron Metabolism Disorders
Lung Diseases
Metabolic Diseases
Respiratory Tract Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on May 25, 2016